News

Applications open for ARUK Doctoral Clinical Fellowship and UKDTN Clinical Trial Placement Pilot Clinicians interested in building a career in dementia clinical research are invited to apply for the Alzheimer’s Research

UKDTN was proud to participate in the Alzheimer’s Association International Conference (AAIC) 2026, held in London. Bringing together more than 10,000 researchers, clinicians, industry leaders and healthcare professionals from across the

Promising Phase 2 findings presented at the Alzheimer’s Association International Conference (AAIC) 2026 have demonstrated that the investigational therapy diranersen slowed cognitive decline while significantly reducing tau pathology in people with

A recent study, led by UKDTN’s Director – Professor Catherine Mummery – evaluated ImmunoBrain’s IBC-Ab002, a monoclonal antibody designed to modulate immune responses associated with Alzheimer’s Disease and support the brain’s

The UK Dementia Trials Network (UKDTN) is pleased to announce its nomination for the Parliamentary Pathfinder – NHS Innovation Adoption Awards 2025-2026, which recognises organisations and partnerships successfully scaling innovation across

Building Momentum in Dementia Research: UKDTN Engages with the Scientific Community at the Alzheimer’s Research UK Research Conference 2026. UKDTN was proud to take part in this year’s Alzheimer’s Research UK

UKDTN launched its first Phase 1b Alzheimer’s trial, dosing the first patient in Europe and streamlining setup across sites, with further trials and collaborations in progress.  

On 3 December 2025, UKDTN convened the UK Industry Liaison Forum at CTAD 2025 in San Diego, bringing together global charities, international academic experts, and industry partners from over 20 pharma and biotech companies worldwide.